Keyphrases
Advanced Breast Cancer
40%
Advanced Triple-negative Breast Cancer
11%
Aromatase Inhibitors
11%
Biosimilar
23%
Brain Metastases
23%
Breast Cancer
92%
Breast Cancer Diagnosis
15%
Breast Cancer Genomics
11%
Breast Cancer Patients
40%
Breast Cancer Recurrence
34%
Cancer Population
11%
Capecitabine Monotherapy
11%
Chemotherapy
14%
Confidence Interval
38%
Copenhagen
13%
Denmark
41%
Development Validation
11%
Dual Blockade
23%
Early Breast Cancer
11%
ER +
17%
Gemcitabine
11%
Hazard Ratio
17%
HER2-positive
11%
HER2-positive Metastatic Breast Cancer
32%
Human Epidermal Growth Factor Receptor 2 (HER2)
68%
Locally Advanced Breast Cancer
11%
Machine Learning Models
11%
Median Overall Survival
29%
Median Progression-free Survival
28%
Meta-analysis
11%
Metastatic Breast Cancer
66%
Metastatic Triple-negative Breast Cancer
11%
National Health Registry
11%
National Registry
15%
Non-interventional Study
11%
Overall Survival
62%
Palbociclib
11%
Pertuzumab
23%
Population-based
23%
Population-based Observational Studies
13%
Prognostic Value
11%
Progression-free Survival
43%
Recurrent Ovarian Cancer
11%
Registry Study
11%
Staging System
11%
Stereotactic Radiosurgery
11%
Targeted Treatment
12%
Trastuzumab
33%
Treatment Line
15%
Treatment Regimen
11%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase Inhibitor
11%
Atezolizumab
11%
Biosimilar Agent
23%
Brain Metastasis
20%
Breast Cancer
100%
C Reactive Protein
11%
Capecitabine
11%
Chemotherapy
27%
Combination Therapy
16%
Disease
16%
Epidermal Growth Factor Receptor 2
21%
Estrogen Receptor
15%
Fulvestrant
11%
Gamma Urogastrone
23%
Gemcitabine
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Metastatic Breast Cancer
85%
Monotherapy
17%
Neoplasm
8%
Observational Study
25%
Ovary Cancer
11%
Overall Survival
63%
Paclitaxel
14%
Palbociclib
11%
Pertuzumab
21%
Progression Free Survival
58%
Receptor
11%
Recurrent Disease
11%
Retrospective Study
13%
Trastuzumab
33%
Medicine and Dentistry
Aromatase Inhibitor
11%
Assessment of Humans
11%
Biosimilar
11%
Brain Metastasis
11%
Breast Cancer
85%
Breast Cancer Screening
11%
C Reactive Protein
11%
Cancer Diagnosis
11%
Capecitabine
12%
Carboplatin
6%
Cohort Analysis
11%
Disease
20%
Doxorubicin
6%
Epidermal Growth Factor Receptor 2
24%
Estrogen Receptor
15%
Fulvestrant
11%
Gamma Urogastrone
23%
Gemcitabine
11%
Hazard Ratio
12%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Malignant Neoplasm
9%
Meta-Analysis
11%
Metastatic Breast Cancer
69%
Monotherapy
17%
Neoadjuvant Chemotherapy
11%
Observational Study
16%
Oncology
5%
Ovarian Cancer
12%
Overall Survival
47%
Paclitaxel
5%
Palbociclib
11%
Pertuzumab
10%
Progression Free Survival
33%
Receptor
9%
Recurrent Ovarian Cancer
11%
Retrospective Study
11%
Spine
5%
Stereotactic Radiosurgery
11%
Systematic Review
11%
Targeted Therapy
17%
Trastuzumab
17%
Triple Negative Breast Cancer
11%
